Baranova Ancha, Liotta Lance, Petricoin Emanuel, Younossi Zobair M
Center for Liver Diseases, Inova Fairfax Hospital, Department of Medicine, Falls Church, VA 22042, USA.
Clin Liver Dis. 2007 Feb;11(1):209-20, xi. doi: 10.1016/j.cld.2007.02.003.
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are examples of complex diseases accompanied by changes in the expression of thousands of genes and a plethora of proteins encoded by these genes. Before the era of high-throughput analysis, typical translational research initiatives, aimed at defining the molecular targets for complex diseases, were performed on gene-by-gene basis. Innovative technologies, such as expression microarrays, mass spectromety, and reverse proteomics, now allow investigators to reveal complex patterns of the expression of biologically active molecules. For this reason, high-throughput approaches may be well suited for studies designed to untangle the molecular basis of the chronic liver diseases such as NAFLD.
非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）是复杂疾病的例子，这些疾病伴随着数千个基因表达的变化以及由这些基因编码的大量蛋白质的变化。在高通量分析时代之前，旨在确定复杂疾病分子靶点的典型转化研究计划是逐个基因进行的。诸如表达微阵列、质谱分析和反向蛋白质组学等创新技术，现在使研究人员能够揭示生物活性分子表达的复杂模式。因此，高通量方法可能非常适合用于旨在阐明诸如NAFLD等慢性肝病分子基础的研究。
